157 related articles for article (PubMed ID: 30647822)
1. Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly.
Ghate SR; Li Z; Tang J; Nakasato AR
Am Health Drug Benefits; 2018 Oct; 11(7):334-343. PubMed ID: 30647822
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with adverse events in patients with metastatic melanoma.
Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
[TBL] [Abstract][Full Text] [Related]
3. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
Bilir SP; Ma Q; Zhao Z; Wehler E; Munakata J; Barber B
Am Health Drug Benefits; 2016 Jun; 9(4):203-13. PubMed ID: 27688833
[TBL] [Abstract][Full Text] [Related]
5. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
6. Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy.
Shah A; Shah R; Kebede N; Mohamed A; Botteman M; Waldeck R; Hussain A
J Med Econ; 2020 Apr; 23(4):330-346. PubMed ID: 31835965
[No Abstract] [Full Text] [Related]
7. Costs associated with adverse events for systemic therapies in metastatic melanoma.
Fu AZ; Li Z; Tang J; Mahmood S; Whisman T; Qiu Y
J Comp Eff Res; 2018 Sep; 7(9):867-879. PubMed ID: 30192155
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
[TBL] [Abstract][Full Text] [Related]
11. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
12. Costs associated with adverse events in patients with metastatic renal cell carcinoma.
Borker R
J Med Econ; 2014 Nov; 17(11):792-7. PubMed ID: 25116694
[TBL] [Abstract][Full Text] [Related]
13. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
[No Abstract] [Full Text] [Related]
14. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
15. An economic evaluation of perioperative adverse events associated with spinal surgery.
Hellsten EK; Hanbidge MA; Manos AN; Lewis SJ; Massicotte EM; Fehlings MG; Coyte PC; Rampersaud YR
Spine J; 2013 Jan; 13(1):44-53. PubMed ID: 23384882
[TBL] [Abstract][Full Text] [Related]
16. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.
Borghaei H; Yim YM; Guerin A; Pivneva I; Shi S; Gandhi M; Ionescu-Ittu R
Lung Cancer; 2018 May; 119():112-119. PubMed ID: 29656745
[TBL] [Abstract][Full Text] [Related]
17. Adverse event-related costs for systemic metastatic breast cancer treatment among female Medicaid beneficiaries.
Irwin DE; Masaquel A; Johnston S; Barnett B
J Med Econ; 2016 Nov; 19(11):1027-1033. PubMed ID: 27206801
[TBL] [Abstract][Full Text] [Related]
18. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens.
Hansen RN; Ramsey SD; Lalla D; Masaquel A; Kamath T; Brammer M; Hurvitz SA; Sullivan SD
Springerplus; 2014; 3():259. PubMed ID: 24926422
[TBL] [Abstract][Full Text] [Related]
19. Assessment of costs associated with adverse events in patients with cancer.
Wong W; Yim YM; Kim A; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Guerin A
PLoS One; 2018; 13(4):e0196007. PubMed ID: 29652926
[TBL] [Abstract][Full Text] [Related]
20. Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis.
Hong L; Huang P; Zheng X; Ye X; Zhao H; Wang J; Shao Y
Front Oncol; 2022; 12():865656. PubMed ID: 35530323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]